rs1033904 - LINC00605 - RPL21P13

Magnitude 2.0 · 1 study on file

Reported associations

• A Genome-Wide Association Study in Human Lymphoblastoid Cells Supports Safety of Mitochondrial Complex I Inhibitor - Unknown journal (n.d.) · Unknown authors · PubMed 33610756

  ABSTRACT: Novel therapeutic strategies for Alzheimer's disease (AD) are of the greatest priority given the consistent failure of recent clinical trials focused on Aβ or pTau. Earlier, we demonstrated that mild mitochondrial complex I inhibitor CP2 blocks neurodegeneration and cognitive decline in multiple mouse models of AD. To evaluate the safety of CP2 in humans, we performed a genome-wide association study (GWAS) using 196 lymphoblastoid cell lines and identified 11 SNP loci and 64 mRNA expression probe sets that potentially associate with CP2 susceptibility. Using primary mouse neurons and pharmacokinetic study, we show that CP2 is generally safe at a therapeutic dose. FULL TEXT: [INTRO] Introduction [INTRO] Increased longevity over the last few decades contributed to the prevalen

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.